IAM chart discussion only, page-1580

First 1580 Last

Share
Profile

Follow
Chev007

260 Posts.

3

05/04/17

23:01

Post #: 23889231
Share

Originally posted by Cheeky_Messiah ↑

Hey Gouldians,

Good points you put down. There's a few that you've noted down that I certainly agree with.
I'm a long term shareholder too and the NAB announcement ticked me off to no end.
Still seething given where we should be and the positivity that should have come out of it.

On the flip side, what will happen shortly will be much better.
My belief is that the Sentry deal is sewn up.

I have no information on this, I'm simply thinking how I'd be running a business.
If somebody had offered me a service that saved me ~40% on a large portion of my costs, I'd sign without thinking.
However, the fact that they've been able to test the services out and slowly roll the Intiger solution throughout their network is a bonus for them.

The impending Sentry announcement isn't what I'm looking forward to though.
What will come over the next few months will be solid revenue numbers which will either point towards the company hitting its ambitious targets or folding under the pressure.

These will be empirical figures that will allow us to quantify the value of future deals and the effect on the share price with future clients.

As I said above, I'm as flat as anybody on here in regards to the NAB deal.
If I didn't believe the company had something decent, I would have sold on one of the bounces after that.
Just like Sower.
My feeling though, is that the gamble in holding will pay off as soon as the Sentry deal is announced and we see some cold hard revenue figures.

After that, we can reassess the value of the company in relation to the share price and the probability they will sign on more clients.

Exciting times if you have the cojones to hold.

Expand

thanks @Cheeky_Messiah, I too subscribe to your sentiment re:IAM current climate, well said. (although not too fussed about the previous Anns).. Thumbs Up

I cannot even hazard a guess as to when we will hear from IAM, although rest assured we will hear from them, absolutely have to -duh. its just a matter of time.... but by golly it is suspenseful hehehe

Hang in there everyone
.

Last edited by Chev007: 05/04/17

IAM Price at posting: 4.8¢ Sentiment: Buy Disclosure: Held
10 Upvote

0 Great analysis

Reply

Top Stories

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 908 more messages in this thread...

First 1580 Last

Add CF1 (ASX) to my watchlist

(20min delay)
Last 2.2¢		Change 0.000(0.00%)		Mkt cap ! $12.58M

Open	High	Low	Value	Volume
2.2¢	2.2¢	2.2¢	$2	91

Buyers (Bids)

No.	Vol.	Price($)
1	150000	2.1¢

Sellers (Offers)

Price($)	Vol.	No.
2.2¢	301916	4

View Market Depth

No.	Vol.	Price($)
1	150000	0.021
1	491617	0.020
1	200000	0.019
3	1434231	0.018
1	1000000	0.017

Price($)	Vol.	No.
0.022	301916	4
0.023	165117	1
0.024	125000	1
0.026	64744	1
0.028	483161	1

Last trade - 13.05pm 07/10/2024 (20 minute delay)

CF1 (ASX) Chart

IAM chart discussion only, page-1580

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

IAM chart discussion only, page-1580

Top Stories

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News